Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 BMS-986205 plus Nivolumab vs Nivolumab in Untreated Metastatic or Unresectable Melanoma
jRCT2080223779Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in melanoma comparing BMS-986205 + nivolumab with Nivolumab + placebo (2 arms). Started Jan 2018; status: completed.
02
Drugs
linrodostatnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2080223779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223779.